BACKGROUND: The treatment of anemia in patients with cardiorenal syndrome (CRS) is based mainly on intravenous (IV) iron therapy and/or erythropoiesis-stimulating agents (ESAs). There are concerns about the safety of ESAs due to a potentially higher risk for stroke and malignancy. OBJECTIVE: We aimed to explore whether IV iron alone is sufficient to improve anemia in CRS patients and to define the predictors of treatment response. METHODS: We retrospectively analyzed data of 81 CRS patient treated for anemia at our clinic. All patients received IV iron for 6 weeks. A subset of patients was additionally given subcutaneous ESAs. The end point was the improvement from baseline in hemoglobin (Hb) and ferritin levels at week 7. RESULTS: We retrieved the files of 81 patients; 34 received IV iron alone and 47 were given IV iron and ESAs (the combination group). The Hb levels significantly increased in both groups (in the IV iron alone group: 10.6 ± 1.1 to 11.9 ±1.1 g/dl, p < 0.001; in the combination group: 10.2 ± 0.9 to 12.4 ± 1.3 g/dl, p < 0.001), but more pronouncedly in the combination group (2.17 vs. 1.24 g/dl; p = 0.001). The platelet count decreased significantly in the IV iron alone group but was unchanged in the combination group. Eighty percent of patients attained a Hb target of 11 g/dl, with no significant difference between the two groups (73.5 vs. 85.1%; p = 0.197). Low baseline Hb was the only predictor of a favorable outcome to treatment. CONCLUSION: Our observational study suggests that IV iron treatment without ESAs may substantially raise the Hb level to ≥11 g/dl in CRS patients. This treatment strategy may reduce the use of ESAs and hence its potential adverse effects.
BACKGROUND: The treatment of anemia in patients with cardiorenal syndrome (CRS) is based mainly on intravenous (IV) iron therapy and/or erythropoiesis-stimulating agents (ESAs). There are concerns about the safety of ESAs due to a potentially higher risk for stroke and malignancy. OBJECTIVE: We aimed to explore whether IV iron alone is sufficient to improve anemia in CRSpatients and to define the predictors of treatment response. METHODS: We retrospectively analyzed data of 81 CRSpatient treated for anemia at our clinic. All patients received IV iron for 6 weeks. A subset of patients was additionally given subcutaneous ESAs. The end point was the improvement from baseline in hemoglobin (Hb) and ferritin levels at week 7. RESULTS: We retrieved the files of 81 patients; 34 received IV iron alone and 47 were given IV iron and ESAs (the combination group). The Hb levels significantly increased in both groups (in the IV iron alone group: 10.6 ± 1.1 to 11.9 ±1.1 g/dl, p < 0.001; in the combination group: 10.2 ± 0.9 to 12.4 ± 1.3 g/dl, p < 0.001), but more pronouncedly in the combination group (2.17 vs. 1.24 g/dl; p = 0.001). The platelet count decreased significantly in the IV iron alone group but was unchanged in the combination group. Eighty percent of patients attained a Hb target of 11 g/dl, with no significant difference between the two groups (73.5 vs. 85.1%; p = 0.197). Low baseline Hb was the only predictor of a favorable outcome to treatment. CONCLUSION: Our observational study suggests that IV iron treatment without ESAs may substantially raise the Hb level to ≥11 g/dl in CRSpatients. This treatment strategy may reduce the use of ESAs and hence its potential adverse effects.
Authors: Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Marcello Tonelli; Amit X Garg; Fabio Pellegrini; Pietro Ravani; Meg Jardine; Vlado Perkovic; Giusi Graziano; Richard McGee; Antonio Nicolucci; Gianni Tognoni; Giovanni F M Strippoli Journal: Ann Intern Med Date: 2010-06-24 Impact factor: 25.391
Authors: Donald S Silverberg; Dov Wexler; Alberto Palazzuoli; Adrian Iaina; Doron Schwartz Journal: Acta Haematol Date: 2009-11-10 Impact factor: 2.195
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Claudine T Jurkovitz; Jerome L Abramson; L Viola Vaccarino; William S Weintraub; William M McClellan Journal: J Am Soc Nephrol Date: 2003-11 Impact factor: 10.121
Authors: Karl Swedberg; James B Young; Inder S Anand; Sunfa Cheng; Akshay S Desai; Rafael Diaz; Aldo P Maggioni; John J V McMurray; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Yan Sun; Michal Tendera; Dirk J van Veldhuisen Journal: N Engl J Med Date: 2013-03-10 Impact factor: 91.245
Authors: Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh Journal: Am J Kidney Dis Date: 2008-08-29 Impact factor: 8.860
Authors: Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach Journal: Blood Transfus Date: 2017-09 Impact factor: 3.443
Authors: Abel Makubi; Johnson Lwakatare; Okechukwu S Ogah; Lars Rydén; Lars H Lund; Julie Makani Journal: Cardiovasc J Afr Date: 2017 Sep/Oct Impact factor: 1.167